NCT00325351 2021-04-08
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
Bayer
Phase 2 Completed
Clinical Trials
13 trialsNCT00350051 2021-04-08
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
Bayer
Phase 2 Completed
NCT00246688 2015-12-31
Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer
Bayer
Phase 2 Completed
NCT00299390 2015-12-31
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
Bayer
Phase 2 Terminated
NCT00432302 2015-12-14
Investigation of Mass Balance of the Test Drug and Major Metabolites
Bayer
Phase 1 Completed
NCT00313248 2015-12-10
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
Bayer
Phase 2 Completed
NCT00160069 2014-12-04
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Bayer
Phase 2 Completed
NCT00288249 2014-12-02
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT00359359 2014-11-04
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
Bayer
Phase 1/2 Completed
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed
NCT00598507 2013-12-11
Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00496379 2013-03-14
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00424060 2012-09-24
Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed